RU2007108037A - PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HEPATITIS C ON THE BASIS OF NON-INFECTIOUS PSEUDOVIRIONES OF THE HEPATITIS C VIRUS - Google Patents

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HEPATITIS C ON THE BASIS OF NON-INFECTIOUS PSEUDOVIRIONES OF THE HEPATITIS C VIRUS Download PDF

Info

Publication number
RU2007108037A
RU2007108037A RU2007108037/13A RU2007108037A RU2007108037A RU 2007108037 A RU2007108037 A RU 2007108037A RU 2007108037/13 A RU2007108037/13 A RU 2007108037/13A RU 2007108037 A RU2007108037 A RU 2007108037A RU 2007108037 A RU2007108037 A RU 2007108037A
Authority
RU
Russia
Prior art keywords
hepatitis
virus
pharmaceutical composition
pseudovirions
encodes
Prior art date
Application number
RU2007108037/13A
Other languages
Russian (ru)
Other versions
RU2375449C2 (en
Inventor
Игорь Геннадьевич Сивов (RU)
Игорь Геннадьевич Сивов
Дмитрий Михайлович Кулиш (RU)
Дмитрий Михайлович Кулиш
Original Assignee
Нейрок Фарма ЛЛС (US)
Нейрок Фарма ЛЛС
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нейрок Фарма ЛЛС (US), Нейрок Фарма ЛЛС filed Critical Нейрок Фарма ЛЛС (US)
Priority to RU2007108037/13A priority Critical patent/RU2375449C2/en
Publication of RU2007108037A publication Critical patent/RU2007108037A/en
Application granted granted Critical
Publication of RU2375449C2 publication Critical patent/RU2375449C2/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (5)

1. Комплементарная ДНК (кДНК) для получения псевдовирионов вируса гепатита типа С, характеризующаяся нуклеотидной последовательностью, кодирующей полипептид с аминокислотной последовательностью, соответствующей SEQ.ID.1, приведенной на фиг.1.1. Complementary DNA (cDNA) for obtaining pseudovirions of hepatitis C virus, characterized by a nucleotide sequence encoding a polypeptide with an amino acid sequence corresponding to SEQ.ID.1 shown in figure 1. 2. Комплементарная ДНК по п.1, характеризующаяся тем, что содержит нуклеотидные последовательности, в которых одна кодирует репликативный комплекс вируса ящура, а другая способна служить субстратом для него, но также кодирует образование белков псевдовирионов вируса гепатита типа С.2. The complementary DNA according to claim 1, characterized in that it contains nucleotide sequences in which one encodes a replicative complex of foot and mouth disease virus and the other is able to serve as a substrate for it, but also encodes the formation of hepatitis C virus pseudovirion proteins. 3. Способ получения псевдовирионов вируса гепатита типа С, характеризующийся тем, что он включает подготовительное культивирование клеток ВНК21, трасформированных последовательностями по пп.1-2, оперативно связанными с промотором-энхансером, способным управлять репликацией и трансляции указанной последовательности ДНК, в подходящей культуральной среде и выделение HCV-подобных вирионов из указанных клеток.3. A method for producing pseudovirion of type C hepatitis virus, characterized in that it includes preparatory cultivation of BHK cells 21 transformed with sequences according to claims 1-2, operably linked to a promoter-enhancer capable of controlling replication and translation of said DNA sequence in a suitable culture medium and isolation of HCV-like virions from these cells. 4. Фармацевтическая композиция для индукции интерферонов и других цитокинов, характеризующаяся тем, что содержит псведовирионы, полученные по п.3 в эффективном количестве и фармацевтически приемлемый носитель.4. A pharmaceutical composition for the induction of interferons and other cytokines, characterized in that it contains pseudovirions obtained according to claim 3 in an effective amount and a pharmaceutically acceptable carrier. 5. Фармацевтическая композиция по п.4, характеризующаяся тем, что она предназначена для предотвращения и лечения состояний, связанных с гепатитом С.5. The pharmaceutical composition according to claim 4, characterized in that it is intended to prevent and treat conditions associated with hepatitis C.
RU2007108037/13A 2007-03-29 2007-03-29 CODING DNA (cDNA) FOR MAKING VIRUS-LIKE PARTICLES OF HEPATITIS C VIRUS, METHOD FOR MAKING VIRUS-LIKE PARTICLES AND BASED PHARMACEUTICAL COMPOSITION RU2375449C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2007108037/13A RU2375449C2 (en) 2007-03-29 2007-03-29 CODING DNA (cDNA) FOR MAKING VIRUS-LIKE PARTICLES OF HEPATITIS C VIRUS, METHOD FOR MAKING VIRUS-LIKE PARTICLES AND BASED PHARMACEUTICAL COMPOSITION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2007108037/13A RU2375449C2 (en) 2007-03-29 2007-03-29 CODING DNA (cDNA) FOR MAKING VIRUS-LIKE PARTICLES OF HEPATITIS C VIRUS, METHOD FOR MAKING VIRUS-LIKE PARTICLES AND BASED PHARMACEUTICAL COMPOSITION

Publications (2)

Publication Number Publication Date
RU2007108037A true RU2007108037A (en) 2008-10-10
RU2375449C2 RU2375449C2 (en) 2009-12-10

Family

ID=39929762

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007108037/13A RU2375449C2 (en) 2007-03-29 2007-03-29 CODING DNA (cDNA) FOR MAKING VIRUS-LIKE PARTICLES OF HEPATITIS C VIRUS, METHOD FOR MAKING VIRUS-LIKE PARTICLES AND BASED PHARMACEUTICAL COMPOSITION

Country Status (1)

Country Link
RU (1) RU2375449C2 (en)

Also Published As

Publication number Publication date
RU2375449C2 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
JP2005102701A5 (en)
JP2008508859A5 (en)
JP2008529558A5 (en)
EP2425848A3 (en) Influenza immunogen and vaccine
JP2020500015A5 (en)
JP2008530975A5 (en)
WO2006045796A3 (en) Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof
JP2009515831A5 (en)
EP2391383B1 (en) Codon-optimized hepatitis b virus core antigen (hbcag)
JP2006501825A5 (en)
JP2016533332A5 (en)
WO2005068639A3 (en) Particle-induced ghrelin immune response
CN1957084A (en) Bone marrow-relevant cell participating the maintenance and/or repair of tissue
CO6150189A2 (en) VACCINES FOR MALARIA
TWI695842B (en) Flavivirus virus like particle
WO2008034388A8 (en) Virus-like particles of capsid proteins from human papillomavirus type 16/58/18/6/11 and the method for preparation and the uses thereof
RU2015155821A (en) VACCINES AGAINST MALARIA
RU2009123028A (en) RESPIRATORY-SYNCITIAL VIRUS (RSV) F-PROTEIN AND ITS APPLICATION
JP2006506942A5 (en)
JP2006504644A5 (en)
WO2006027300A3 (en) Carrier conjugates of gnrh-peptides
DK1441764T3 (en) Antigen Arrays Including RANKL for the Treatment of Bone Disease
JP2010506926A5 (en)
CN1449407A (en) Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acidor a glutamine in the form of physiologically acceptable
JP2019505567A5 (en)

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20120330